Viral bronchiolitis is a common clinical syndrome aff ecting infants and young children. Concern about its associated morbidity and cost has led to a large body of research that has been summarised in systematic reviews and integrated into clinical practice guidelines in several countries. The evidence and guideline recommendations consistently support a clinical diagnosis with the limited role for diagnostic testing for children presenting with the typical clinical syndrome of viral upper respiratory infection progressing to the lower respiratory tract. Management is largely supportive, focusing on maintaining oxygenation and hydration of the patient. Evidence suggests no benefi t from bronchodilator or corticosteroid use in infants with a fi rst episode of bronchiolitis. Evidence for other treatments such as hypertonic saline is evolving but not clearly defi ned yet. For infants with severe disease, the insuffi cient available data suggest a role for high-fl ow nasal cannula and continuous positive airway pressure use in a monitored setting to prevent respiratory failure.
Introduction
Acute bronchiolitis, a viral infection of the lower respiratory tract, is one of the most substantial health burdens for infants and young children worldwide. 1 Respiratory syncytial virus is the most prevalent viral cause of bronchiolitis in infants. Estimates suggest that about 34 million new cases of lower respiratory infection due to respiratory syncytial virus occur globally in children younger than 5 years, with 3·4 million admissions to hospitals and about 199 000 deaths per year, predominantly in the developing world. 2 In developed countries such as the USA, bronchiolitis is the most common reason for admission to hospital in the fi rst 12 months of life, 3 accounting for approximately 100 000 infant admissions annually. Although admissions to hospital have declined from 2000 to 2010, emergency department visits have increased, in addition to increased use of mechanical ventilation and hospital charges. 4, 5 The clinical management remains challenging despite the frequency, global reach, economic cost, and morbidity and mortality associated with bronchiolitis. Several treatment strategies (including bronchodilators and corticosteroids) showed no eff ect in pooled metaanalyses, making supportive care the hallmark of current therapy. In this Seminar, we aim to summarise the current evidence for the epidemiology, pathophysiology, diagnostic approach, and management of acute viral bronchiolitis.
Epidemiology
Bronchiolitis is a seasonal infection, with the season typically beginning in late October in the temperate northern hemisphere, peaking in January or February, and ending in April. 6 Globally, independent of region, respiratory syncytial virus infection peaks consistently during annual or biannual epidemics. Although the peak and duration of these epidemics vary worldwide, they are consistent year-to-year within a country. 7 Some data suggest that climate might also be associated with prevalence of respiratory syncytial virus infection, with global surveillance suggesting that infection peaks during wet months in areas with high precipitation and during cooler months in hot regions. 7 Indoor crowding in population-dense areas during rainy seasons or cooler months might be one factor that facilitates viral transmission. 8 Additionally, weather-related factors, such as inhalation of cold and dry air that might impair ciliary function, the airway mucosa, and inhibition of temperature-dependent antiviral responses, might infl uence both disease transmission and severity. 9, 10 Altitude, climate, and meteorological conditions (such as wind speed and dew point) have been shown to have a modest association with bronchiolitis. 11, 12 Furthermore, air pollutants, such as ozone and traffi c pollutants, have been associated with exacerbations of respiratory infections in children younger than 5 years. [13] [14] [15] Environmental tobacco smoke has been associated with increased risk for respiratory syncytial virus-attributable admission to hospital and disease severity in those admitted. 16, 17 As with other respiratory viral infections, the risk of severe respiratory syncytial virus bronchiolitis might be greater in boys than in girls. 18, 19 This diff erence might be due to diff erences in lung and airway development, and by genetic factors. 8, 20 Pathophysiology Bronchiolitis is characterised by extensive infl ammation and oedema of the airways, increased mucus production, and necrosis of airway epithelial cells. 21 Respiratory syncytial virus binds to epithelial cells and replicates, resulting in epithelial necrosis and ciliary destruction. 21, 22 The cell destruction triggers an infl ammatory response with proliferation of polymorphonuclear cells and lymphocytes. The submucosa and adventitial tissues become oedematous with increased mucus secretion. 22 Plugs composed of cellular debris and mucus form in the bronchiole lumens leading to bronchiolar obstruction, air trapping, and diff erent degrees of lobar collapse. 21 
Microbiology
Molecular testing has led to an improved understanding of the viruses associated with bronchiolitis. Respiratory syncytial virus remains the most commonly identifi ed virus, detected in 41-83% of patients. [23] [24] [25] [26] [27] [28] Other viruses associated with bronchiolitis include rhinovirus, metapneumovirus, coronavirus, human bocavirus, infl uenza virus, adenovirus, and parainfl uenza virus. 24, 25, 27, 29, 30 Studies have investigated whether severity of illness, as measured by need for hospital admission, length of hospital stay, intensive care unit admission, repeated emergency department visits, and apnoea, is associated with specifi c viral infections or co-infections, but the evidence is confl icting. Data from some studies have shown that in infections involving a single virus, respiratory syncytial virus is associated with a more severe course compared with other viruses. 31, 32 Up to 30% of children with bronchiolitis are found to have co-infections with two other viruses, 29 with the combination of respiratory syncytial virus and rhinovirus being the most commonly reported. 29 Some evidence suggests that co-infection in bronchiolitis, particularly respiratory syncytial virus in combination with rhinovirus or metapneumovirus, could be associated with a more severe disease course compared with infection by a single virus. 25, 30, 31, 33, 34 However, other studies do not confi rm this association. 24, 26 Furthermore, although use of nucleic acid amplifi cation tests has greatly improved our ability to detect viruses present in respiratory infections, studies using these technologies have also found at least one respiratory virus in up to 30% of children younger than 6 years with no respiratory symptoms. [35] [36] [37] These viruses might be detected because of asymptomatic colonisation, incubation before clinical infection, or prolonged viral shedding post-infection. The confl icting evidence and high prevalence of respiratory viruses in asymptomatic children suggest no indication at this time that management should vary based on presumed viral cause and presence, or absence of viral co-infections.
Clinical presentation and diff erential diagnosis
The diagnosis of bronchiolitis is clinical and thus requires a clinician to recognise signs and symptoms of viral lower respiratory tract infection in young children. Peak incidence occurs between 3 months and 6 months of age. 38 Since the early clinical defi nition by Court, and as noted in recent practice guidelines, the most specifi c defi nition is in infants. [38] [39] [40] Although the same physiology can occur in toddlers older than 12 months, many clinical trials have excluded these children or have included them as a small subgroup of patients. Bronchiolitis in toddlers can overlap with other conditions such as viral-induced wheezing and asthma, and application of evidence from trials predominantly assessing infants might not be appropriate. Further eff orts to focus the defi nition might assist eff orts to standardise care.
The classic clinical presentation of bronchiolitis starts with symptoms of a viral upper respiratory infection, such as nasal discharge, that progress to the lower respiratory tract over several days (fi gure 1). Timing of symptom progression can vary, and young infants can present with apnoea. Lower respiratory tract symptoms of bronchiolitis include persistent cough, tachypnoea, and increased work of breathing, as shown by intercostal or supraclavicular retractions, use of abdominal muscles, grunting, or nasal fl aring. Auscultatory fi ndings include crackles and wheeze. A hallmark characteristic of bronchiolitis is the minute-to-minute variation in clinical fi ndings, as mucus and debris in the airways are cleared by coughing or as the child's state changes from sleep to agitation. This variation can confound assessment, and often requires several examinations over a period of observation. Nasal congestion can also confound the clinical assessment. Nasal suctioning might help to ascertain which fi ndings are truly from the lower airways. Fever can be present in about a third of infants with bronchiolitis, but it is usually present early in the illness with a temperature less than 39°C. 38 The median duration of symptoms is about 2 weeks, with 10-20% of infants still having symptoms at 3 weeks after onset. 38, 41 Various clinical scores have been shown in studies and clinical protocols to correlate with disease severity and improvement. 42, 43 Although documentation of a score can be useful as an objective measure, individual scores are not highly predictive, and they should be repeated and combined with other measures of severity for a universal assessment to guide decision making. The diff erential diagnosis for bronchiolitis includes considerations of various infectious and non-infectious causes. Absence of upper respiratory symptoms should raise suspicion of other causes of respiratory distress in young infants, including cardiac disease, congenital airway abnormalities such as a vascular ring, or foreign body aspiration. Other infections can resemble or complicate bronchiolitis. Pertussis should be considered in infants with severe or paroxysmal cough, or with known exposure. Bacterial infections complicating viral bronchiolitis, including otitis media or pneumonia, might present as a new fever or worsening status later in the course of illness.
Various risk factors have been associated with progression to severe bronchiolitis. Those supported by the strongest evidence include presence of chronic lung disease of prematurity and haemodynamically important congenital heart disease, with immunodefi ciency and neuromuscular disorders also considered as high risk in practice guidelines. 38, 39 Young infants (aged <2-3 months) and those with a history of premature birth (especially <32 weeks' gestation) are also at high risk for progression and can present with apnoea without other clinical fi ndings. Studies assessing the risk for further apnoea in hospital have found it to be limited to infants less than 1 month for full-term infants, 48 weeks postconceptional age for preterm infants, or those with apnoea observed before admission. 44
Diagnostic investigations

Pulse oximetry
Bronchiolitis is a clinical diagnosis based on history and physical examination, according to consensus across national guidelines. For infants with a typical presentation of bronchiolitis, routine imaging or laboratory testing is not recommended, as they increase costs without evidence for benefi t (table).
Appropriate use of pulse oximetry monitoring and initiation of oxygen for bronchiolitis have received increasing attention in studies and practice guidelines. Findings suggest that arbitrary thresholds for oxygen administration might drive hospital admissions and prolong hospital length of stay. These outcomes represent only part of the morbidity of bronchiolitis, but developing evidence suggests that intermittent hypoxaemia might occur commonly in otherwise stable infants with bronchiolitis and raises questions as to whether this factor should be used as a sole indication for admission to hospitals. A Canadian randomised trial found reduced admissions to hospital from the emergency department without any increase in revisits when pulse oximeters displayed values 3% higher than the actual value, suggesting that arbitrary pulse oximetry thresholds result in unnecessary admissions. 51 A similar trial in the UK in the hospital setting found that reduction of the oxygen threshold from 94% to 90% resulted in earlier discharge from the hospital without any evidence of adverse outcomes. 52 A US trial comparing intermittent versus continuous pulse oximetry in non-hypoxaemic infants in hospitals found similar outcomes between the groups. 53 This US trial and other evidence supports recommendations in US practice guidelines that clinicians use a threshold of 90% for initiation of oxygen, whereas UK guidelines recommend 92%. 38, 39 As the child improves, reduction in intensity of monitoring to intermittent checks is appropriate. A recent study using blinded oximetry at home showed that a substantial proportion of infants with bronchiolitis who are otherwise doing well have oxygen desaturations less than 90%, particularly during sleep, further calling into question arbitrary thresholds for hospital admissions and initiation of oxygen. 54 This evidence will probably lead to eff orts to reduce continuous monitoring in children without other indications for monitoring.
Imaging
The majority of children with bronchiolitis have either normal radiographs or radiographic fi ndings consistent with simple bronchiolitis, [55] [56] [57] [58] including peribronchial thickening, hyperinfl ation, and atelectasis. One prospective study 58 of routine radiographs as part of the assessment for bronchiolitis in the emergency department reported airspace disease in 17 (7%) of 246 patients. Despite the low prevalence of radiographic pneumonia, this and other studies have reported an increase in antibiotic prescription after radiographs are performed, because of non-specifi c fi ndings that infl uence clinicians' decisions. 58, 59 Factors that have been associated with defi nite focal infi ltrates consistent with pneumonia include hypoxia (oxygen saturation <92%), [56] [57] [58] 60 grunting, persistently focal crackles, and fever (especially >39°C). 38 Chest radiographs should only be considered in patients when the presentation is not classic for bronchiolitis. These situations include when NICE (UK), 2015 38 AAP (USA), 2014 39 another diagnosis (such as foreign body aspiration) is high on the diff erential diagnosis, when a child is severely ill and respiratory failure is imminent, and when symptoms are progressing or not resolving according to the typical disease course expected for bronchiolitis. Lung ultrasound is increasingly used to assess cardiopulmonary conditions in adults and children. Several studies have investigated the use of lung ultrasound in the diagnosis of bronchiolitis. Two small studies found that ultrasound fi ndings in infants with bronchiolitis correlate with clinical fi ndings, and might be more specifi c than chest radiography, 61, 62 but further studies are needed to establish whether there is a role for ultrasound in diagnosis or assessment of severity.
Viral testing
With the development of PCR to detect respiratory viruses in the nasopharynx, interest in the use of viral testing for causative diagnosis in bronchiolitis has increased. Virological testing, however, does not generally assist in management and is insuffi cient to predict outcomes. 30, 63 Many national guidelines therefore recommend against routine virological testing in bronchiolitis (table) . Recent studies suggest that higher respiratory syncytial virus genomic load, measured using quantitative PCR, might be associated with increased length of stay, use of respiratory support, and need for intensive care, in addition to recurrent wheezing, compared with lower viral loads. 28, 31, 32, 64 Further study is warranted to confi rm this association and clarify whether viral load measurement improves understanding of disease pathophysiology and severity. Several guidelines recommend using respiratory syncytial virus testing to guide cohorting of patients; however, the viruses most likely to cause bronchiolitis are all transmitted in a similar fashion (close contact with large-particle aerosols or direct contact with contaminated fomites). [65] [66] [67] Thus, infection control might not be dependent on the identifi cation of specifi c viruses, but rather on following strict precautions including hand hygiene, separating infants in shared hospital rooms by more than 1 m, and other infection control procedures. 65 Additionally, given the sensitivity of PCR testing, results should be interpreted with caution. Certain viruses, such as rhinovirus, might be detected because of viral shedding from an unrelated illness or colonisation; whereas certain other viruses, such as respiratory syncytial virus and metapneumovirus, are almost always associated with an acute infection.
Blood and urine testing
Blood and urine testing is not routinely recommended as part of standard practice in the diagnostic work-up of bronchiolitis (table) . A blood gas measurement should not be routinely obtained in infants with bronchiolitis, unless there are signs of impending respiratory failure or severe distress. Proportions of serious bacterial infections, especially bacteraemia and meningitis, are very low in infants with bronchiolitis. 68 Abnormal white blood cell count is rarely useful in predicting serious bacterial infections in children infected with respiratory syncytial virus. 69 Guidelines universally do not recommend complete blood counts in infants with bronchiolitis unless blood count is part of assessment for a fever in infants younger than 1-2 months. Similarly, given that bacteraemia is exceedingly rare (with cited proportions of <0·1% in the post-pneumococcal vaccine era), blood cultures should not be routinely performed, except in the septic work-up of infants younger than 1-2 months, 70, 71 or in those with severe illness and signs of sepsis. Hydration status is an important consideration in infants with bronchiolitis and should be determined by clinical examination. Routine measurement of serum electrolytes is of little value in the majority of infants.
Urinary tract infections in infants with bronchiolitis occur with greater frequency than do bacteraemia and meningitis, with proportions ranging from 1% to 7%. 68, 71, 72 It is reasonable to obtain a urinalysis and urine culture for infants aged less than 60 days with fever and for older febrile infants who have risk factors for urinary tract infections, 73 but urine should not be routinely obtained in all infants with bronchiolitis.
Management Bronchodilators
Current recommendations for management of bronchiolitis focus on agents to treat the patho physiological eff ects of viral lower respiratory infection (eg, bronchodilators and hypertonic saline). Specifi c antivirals such as ribavirin to treat respiratory syncytial virus infection are not recommended in practice guidelines for typical cases of bronchiolitis because of challenging delivery methods, high cost, and potential health risks to caregivers. Multiple new agents for prevention and treatment are under investigation and might become available in the future, including immunoglobulins, small interfering RNA interference, fusion inhibitors, and small molecules. 74 Numerous studies have assessed the role of bronchodilators for the treatment of bronchiolitis, and systematic reviews have found no consistent benefi t. A 2014 Cochrane Collaboration systematic review identifi ed 30 studies assessing bronchodilators, predominantly salbutamol and excluding epinephrine, and 21 studies that looked specifi ally at clinical scores found no evidence of benefi t in any outcomes for infants admitted to hospitals. 75 In outpatients, oxygen saturation, admission to hospital, or time to resolution of symptoms did not improve with bronchodilator usage compared with placebo. For outpatient studies assessing short-term change in pooled clinical scores, the reviewers found a small signifi cant diff erence in mean score (Z=2·26; p=0·024) that was of small eff ect with minimal clinical importance (fi gure 2). Outpatient studies were heterogeneous (I²=81%; p<0·00001), and those showing benefi t in scores tended to include older children and children with recurrent wheezing.
Nebulised epinephrine was assessed in another Cochrane Collaboration systematic review. 76 This review found no benefi t for epinephrine compared with placebo for inpatients in hospital length of stay or other outcomes. A multicentre Scandinavian study published after this Cochrane review found that inpatients receiving standing doses of epinephrine had longer length of stay compared with inpatients receiving as-needed epinephrine or placebo. 77 For outpatients, the Cochrane review found a diff erence in the numbers of admissions associated with epinephrine treatment during the time of an emergency department visit, but not during the overall course of illness when assessed at 1 week. Clinical practice guidelines including those from the USA, UK, and Canada do not recommend treatment with bronchodilators for bronchiolitis because of this evidence (table) . 38, 39, 45 
Nebulised hypertonic saline
Nebulised hypertonic saline is thought to reduce airway oedema, decrease mucus plugging, improve mucociliary clearance, and rehydrate the airway surface liquid in infants with bronchiolitis. 78 These physiological changes are extrapolated from the cystic fi brosis literature, 79, 80 and the pathophysiological processes in acute bronchiolitis are diff erent. Therefore, the theoretical benefi ts of hypertonic saline seen in cystic fi brosis might not be present in infants with acute viral bronchiolitis. Although initial trials demonstrated some ability of hypertonic saline to decrease hospital length of stay and transiently improve clinical severity score, [81] [82] [83] more recent trials demonstrated confl icting results. [84] [85] [86] [87] [88] [89] [90] The trials that showed the largest benefi t were done in hospitals with lengths of stay more than 72 h; thus, hypertonic saline for infants in countries and institutions in which the length of stay approaches or exceeds 72 h might be benefi cial at reducing length of stay. The confl icting results are
Figure 2: Meta-analysis of studies assessing average clinical score after treatment in patients with bronchiolitis receiving bronchodilators versus placebo
Test for heterogeneity in the inpatient studies demonstrated low inconsistency between the nine studies (I²=36%; p=0·13) and the summary eff ect was not signifi cant (Z=1·06; p=0·29), the outpatient studies demonstrated very high inconsistency between the 12 studies (I²=81%; p<0·00001) and the summary eff ect was signifi cant (Z=2·26; p=0·024), and the overall heterogeneity of the meta-analysis demonstrated high inconsistency between the 21 studies (I²=73%; p<0·00001) and the overall summary eff ect was signifi cant (Z=2·4; p=0·016). IPR=ipratropium. SAL=salbutamol. neb=nebulised. Reproduced from Gadomski and Scribani, 75 refl ected in the diff erences in recommendations across national guidelines (table) , with some countries not recommending hypertonic saline, some recommending use for all inpatients, and some recommending use only in moderate to severe illness. The largest systematic review and meta-analysis, published in 2015, examined 24 trials and 3209 patients. 91 Infants receiving hypertonic saline had a signifi cant diff erence in hospital length of stay of -0·45 days (95% CI -0·82 to -0·08; p=0·01) compared with those receiving 0·9% saline or standard care. In seven trials, hypertonic saline reduced the risk of admission to hospital by 20% (risk ratio 0·8; 95% CI 0·67-0·96) compared with 0·9% saline. No substantial adverse eff ects of hypertonic saline were noted in this systematic review. Although the results of this meta-analysis were signifi cant, attention should be paid to the outer limits of the confi dence intervals, which approach no diff erence, and to the clinical relevance of these diff erences. A second 2015 meta-analysis of 15 trials and 1922 patients found a smaller, but signifi cant, decrease in length of stay by -0·36 days (95% CI -0·5 to -0·22; p<0·001) in those who received hypertonic saline (fi gure 3). 92 This study found a discrepancy between the overall combined eff ect of all studies on length of stay and the negative results from the largest trials, allowing the authors to conclude that neither individual trials nor pooled estimates provide a strong evidence-based foundation for the use of hypertonic saline. Both meta-analyses showed substantial heterogeneity across studies (I²=82·1%, p<0·001; 91 and I²=77·8%, p=0·029 92 ). A recent reanalysis of the fi rst 2015 meta-analysis removed two outlying Chinese studies and accounted for imbalances in day of illness at presentation. 93 These analyses resolved the heterogeneity and found that hypertonic saline does not reduce length of stay in infants admitted to hospitals with bronchiolitis (mean diff erence in length of stay removing outliers -0·21 days; 95% CI -0·43 to 0·02; mean diff erence in length of stay accounting for day of illness imbalance 0·02 days; 95% CI -0·14 to 0·17). Large trials have not demonstrated benefi t for hypertonic saline and this meta-analysis found no eff ect of hypertonic saline on length of stay after adjustment for outliers and imbalances. The decision to undertake future trials is controversial given the positive results of some metaanalyses and negative results of others.
Corticosteroids
Multiple studies have examined the role of corticosteroids in the management of children with bronchiolitis. Data from two large multicentre trials have shown no benefi t to corticosteroids alone in reducing admissions to hospital, 94, 95 and a 2013 Cochrane Collaboration review supports the results of these studies. 96 This review included only studies that enrolled children younger than 24 months with a fi rst episode of wheezing and signs of a viral illness. Among the included eight outpatient studies (1824 participants) comparing corticosteroids with placebo there was no reduction in admission at day 1 (Z=1·05; p=0·3) or day 7 (Z=1·38; p=0·17) after enrolment (fi gure 4), clinical scores, length of stay in the emergency department, or length of time to resolution of symptoms. Among the nine inpatient studies (772 participants), length of hospital stay was not reduced. 96 On the basis of this evidence, multiple clinical practice guidelines recommend against the use of corticosteroids for infants with bronchiolitis (table) . Although clinicians report considering a family or personal history of atopy when deciding whether to treat infants with bronchiolitis with corticosteroids, 41 there is no evidence that such infants receive any benefi t from corticosteroid treatment. [94] [95] [96] Evidence for the presence or absence of respiratory syncytial virus infection in these infants being associated with a response to corticosteroids is also unavailable. 94, 95 Authors from a large study with a factorial design have suggested, in an unadjusted analysis, that high-dose corticosteroids in combination with nebulised epinephrine might reduce admissions for outpatients with bronchiolitis by day 7, 95 but these results are considered exploratory. 39, 45 
High-fl ow oxygen and respiratory support
Non-invasive technologies to improve oxygenation and ventilation for bronchiolitis include humidifi ed high-fl ow nasal cannula oxygen and continuous positive airway pressure. 97 High-fl ow nasal cannula allows delivery of high fl ows (usually 1-2 L/kg per min) with humidifi cation and a cannula designed to improve patient tolerance. It has been used widely in premature infants, but the mechanisms of action are unclear, in particular whether it might deliver positive end-expiratory pressure in some conditions. Evidence for effi cacy of high-fl ow nasal cannula is predominantly observational, with studies documenting 
in patients with bronchiolitis receiving corticosteroids versus placebo
Test for heterogeneity in studies assessing admission at day 1 demonstrated very low inconsistency between the ten studies (I²=0%; p=0·55) and the summary eff ect was not signifi cant (Z=1·05; p=0·30), and studies assessing admission at day 7 demonstrated low inconsistency between the six studies (I²=32%; p=0·21) and the summary eff ect was not signifi cant (Z=1·38; p=0·17). G=glucocorticoid. P=placebo. S=salbutamol. E=epinephrine. Reproduced from Fernandes and colleagues, 96 by permission of John Wiley and Sons.
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Risk ratio (95% CI) improved respiratory parameters and reduced intubation rates after implementation. 97 One small randomised trial compared high-fl ow nasal cannula with hypertonic saline and found no diff erence in change in respiratory score. 98 Concerns about high-fl ow nasal cannula include the potential for rapid deterioration if the infant is not closely monitored and costs associated with overuse. Continuous positive airway pressure has been studied in intensive care settings in observational studies and several small trials, with some evidence of improved respiratory parameters. 97 The UK guidelines recommend considering continuous positive airway pressure in children with impending respiratory failure from bronchiolitis.
Antibiotics
Antibiotic overuse in children with bronchiolitis probably occurs because of concerns about the presence of fever, the young age of aff ected patients, diffi culty diff erentiating atelectasis from infectious consolidation on chest radiograph, and concern for undetected secondary bacterial infection. Bronchiolitis, however, has a clear viral cause and the occurrence of secondary bacterial infections is low, with a risk of bacteraemia or meningitis of less than 1%. 99 A detailed review of randomised clinical trials found that routine use of antibiotics did not improve duration of symptoms, length of hospital stay, need for oxygen therapy, or hospital admission. 38 Overuse of antibiotics is known to result in unnecessary adverse eff ects on the patient, and the development of antimicrobial resistance. Routine use should be avoided unless there is clear evidence of a secondary bacterial infection (table) . Acute otitis media has been documented in up to 60% of infants with bronchiolitis. 100, 101 Antibiotic use for acute otitis media in bronchiolitis should follow established evidence and guidelines for acute otitis media. 102 Macrolide antibiotics have anti-infl ammatory properties that might have potential benefi t in mitigating the infl ammation present in bronchiolitis. Two randomised trials found that there was no diff erence between azithromycin and placebo in hospital length of stay, need for oxygen, or hospital re-admission. 103, 104 Another randomised trial found that azithromycin lowered nasal interleukin-8 concentrations, prolonged time to subsequent wheezing episodes, and resulted in fewer days with respiratory symptoms in the year following the bronchiolitis episode compared with placebo. 105 Finally, a US multicentre study found that in children aged 12-72 months with a history of recurrent severe lower respiratory tract infections, early administration of azithromycin during a lower respiratory tract infection reduced the likelihood of progression to a severe infection, but it is not clear whether the underlying disease in these children was bronchiolitis or some other disease process. 106 Given the current evidence, routine use of macrolides is not recommended in bronchiolitis and more research is needed to clarify any potential role it might have in the future.
Supportive therapies
Hydration, suctioning, and chest physiotherapy have been suggested as supportive therapies. Infants with bronchiolitis might have diffi culty feeding because of nasal congestion and increased work of breathing; thus, hydration remains a cornerstone of therapy. A multicentre study of 759 infants younger than 12 months admitted to hospital with bronchiolitis showed no benefi t of intravenous fl uids compared with administration of fl uids by nasogastric tube in mean length of stay, admission to the intensive care unit, need for ventilatory support, and adverse events. This trial also found that a nasogastric tube might be easier to place than an intravenous line in these infants. 107 Most guidelines recommend either nasogastric or intravenous fl uids to maintain hydration, with the UK and Scottish guidelines preferring nasogastric or orogastric hydration in those that can tolerate it compared with intravenous hydration (table). If intravenous fl uids are used, isotonic fl uids are preferred to avoid risk of hyponatraemia. 38 Because infants are obligate nasal breathers, nasal suctioning has been suggested to help with clearing of the nares, improve the work of breathing, and improve feeding; however, suctioning might irritate the nasal mucosa and result in oedema. No randomised controlled trials have examined the role of nasal suctioning in bronchiolitis. The insuffi cient available evidence includes a retrospective cohort study of 740 infants 108 and a small observational study of 40 infants. 109 These studies suggest that deep suctioning might increase length of stay for inpatients, 108 infrequent suctioning is associated with an increased length of stay, 108 and oxygen saturation might increase after suctioning. 109 To draw conclusions about causality from these observational studies is diffi cult, because the potential for confouding by indication exists (eg, sicker children might be more likely to receive deep suctioning). Evidence suggests that oxygen saturation increases after nasal irrigation even without suctioning. 110 Current guidelines give diff ering recommendations with regard to suctioning; those that support its use recommend only superfi cial suctioning rather than deep suctioning (table) . 38, 39, 45 Chest physiotherapy use in bronchiolitis appears to vary by country. 111, 112 A recent Cochrane Collaboration review of 12 studies (1249 participants) demonstrated no evidence of benefi t to any type of chest physiotherapy among inpatients in length of stay, oxygen saturation, or respiratory parameters. 113 No published guidelines routinely recommend chest physiotherapy for the management of uncomplicated bronchiolitis in otherwise healthy children without respiratory comorbidities (table) . 38, 39, 45 Prognosis Much work has been published about the risk of developing recurrent wheezing and asthma following bronchiolitis in infancy. [114] [115] [116] Studies have followed birth cohorts to determine the risk of subsequent wheezing after lower respiratory tract infection in young childhood, and cohorts of children admitted to hospital with bronchiolitis. [114] [115] [116] [117] Overall, admission to hospital with bronchiolitis at a young age is associated with an increased risk of recurrent wheezing. Studies report that 17-60% of children with bronchiolitis might develop recurrent wheezing in the years following their initial admission to hospital. A large study from Taiwan that followed up 1981 children admitted with bronchiolitis before age 3 years found that by age 10 years, 351 (17·7%) of 1981 children with bronchiolitis had a diagnosis of asthma compared with 2159 (11·7%) of 18 527 controls (hazard ratio 1·58; 95% CI 1·41-1·71). 118 One small cohort study of 138 patients has suggested that 18 (39%) of 46 children admitted with bronchiolitis before 12 months have asthma by 18 years compared with eight (9%) of 92 controls. 115 However, another study that followed a birth cohort of 1246 children found that although lower respiratory tract infection in childhood was associated with an increased risk of recurrent wheezing, this association decreased with age and was not signifi cant by age 13 years. 116 Most children in this cohort had mild illness not requiring hospital admission, and severity of illness might be associated with the increased risk of asthma. 119 The question remains whether respiratory infection at a young age itself predisposes children to asthma through damage or alteration of lung function, or whether children with severe bronchiolitis might have individual risk factors (such as altered immune response or airway function) that predisposes them to both severe bronchiolitis and recurrent wheezing. 8
Knowledge gaps and controversies
Substantial knowledge gaps and controversies exist in the management of acute bronchiolitis. The role of nebulised hypertonic saline in acute management is not clear, resulting in confl icting recommendations across clinical guidelines (table) . Although meta-analyses suggest a small reduction of length of stay, these analyses are limited by heterogeneity, not accounting for duration of illness, and not considering the role of outlying study populations. 91 Two large multicentre trials do not support a clinically signifi cant diff erence in length of stay for inpatients and there is no clear evidence of cost benefi t. 4, [89] [90] [91] 120 While the same meta-analysis suggests a possible reduction in admissions for outpatients, the confi dence intervals were wide and the studies were also heterogeneous. 91 No multicentre studies of nebulised hypertonic saline have been completed in outpatients. Although the evidence is increasing that hypertonic saline has little role in meaningfully reducing the length of stay, its role in outpatients is less clear. A large outpatient multicentre study could clarify whether there is any benefi t.
Evidence also suggests that combined therapy with nebulised epinephrine and corticosteroids might reduce admissions to hospital. 95 Synergy between corticosteroids and β2 agonists is well documented in clinical trials of asthma management. [121] [122] [123] [124] Basic science literature also shows that β2 agonists and corticosteroids enhance each other's eff ectiveness, particularly with regard to antiinfl ammatory gene expression. 125, 126 Because of the economic burden of bronchiolitis and the plausible basic and clinical evidence for synergy, a large and multicentre trial is needed to ascertain whether combined therapy with epinephrine and corticosteroids is benefi cial.
Oxygen saturation and the use of pulse oximetry play an important role in the decision to admit infants with bronchiolitis to hospital and in the length of their hospital stay. [51] [52] [53] [54] [55] [56] [57] [58] [59] Clinical practice guidelines also give confl icting guidance on the level of oxygen saturation at which admission should be considered. Furthermore, a substantial proportion of discharged infants have episodes of transient desaturation. 54 Again, in view of the large health-care costs associated with hospital admission in bronchiolitis, further research is needed to clarify the level of oxygen saturation requiring admission, the role of continuous and spot measurements of oxygen saturation, and the clinical importance of transient desaturations in otherwise stable young infants.
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